These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30054709)

  • 1. Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial.
    Zhang W; Du C; Sun Y; Yang L; Cui C; Jiang Z; Wang C; Wang J; Zhou A
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):655-660. PubMed ID: 30054709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study.
    Jin M; Liu HL; Xue J; Ma H; Liu JL; Lin ZY; Wang J; Bao LQ; Luo ZG; Yu XJ; Li S; Hu JL; Zhang T
    Oncologist; 2024 Oct; 29(10):e1406-e1418. PubMed ID: 38990195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer.
    He MM; Wang F; Jin Y; Yuan SQ; Ren C; Luo HY; Wang ZQ; Qiu MZ; Wang ZX; Zeng ZL; Li YH; Wang FH; Zhang DS; Xu RH
    Cancer Sci; 2018 Nov; 109(11):3575-3582. PubMed ID: 30281875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study.
    Chang C; Li X; Cao D
    BMC Cancer; 2021 May; 21(1):545. PubMed ID: 33985455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
    Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
    Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
    Symonds L; Linden H; Gadi V; Korde L; Rodler E; Gralow J; Redman M; Baker K; Wu QV; Jenkins I; Kurland B; Garrison M; Smith J; Anderson J; Van Haelst C; ; Specht J
    Clin Breast Cancer; 2019 Apr; 19(2):e283-e296. PubMed ID: 30737173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
    Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J
    J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.
    Ikeda M; Ioka T; Ito Y; Yonemoto N; Nagase M; Yamao K; Miyakawa H; Ishii H; Furuse J; Sato K; Sato T; Okusaka T
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):163-9. PubMed ID: 22677367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites.
    Takahara N; Isayama H; Nakai Y; Ishigami H; Satoi S; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Yamaguchi H; Tada M; Kitayama J; Watanabe T; Koike K
    Invest New Drugs; 2016 Oct; 34(5):636-42. PubMed ID: 27339809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
    Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of S1 monotherapy or combined with nab-paclitaxel in advanced elderly pancreatic cancer patients: A meta-analysis.
    Chen Y; Gu J; Yin M; Wang C; Chen D; Yang L; Chen X; Lin Z; Du J; Cui S; Ma C; Luo H
    Medicine (Baltimore); 2021 Jun; 100(25):e26342. PubMed ID: 34160399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study.
    Catalano M; Roviello G; Conca R; D'Angelo A; Palmieri VE; Panella B; Petrioli R; Ianza A; Nobili S; Mini E; Ramello M
    Curr Cancer Drug Targets; 2020; 20(11):887-895. PubMed ID: 32957885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
    Sugimoto N; Fujitani K; Imamura H; Uedo N; Iijima S; Imano M; Shimokawa T; Kurokawa Y; Furukawa H; Goto M
    Anticancer Res; 2014 Feb; 34(2):851-7. PubMed ID: 24511022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302).
    Tamura S; Taniguchi H; Nishikawa K; Imamura H; Fujita J; Takeno A; Matsuyama J; Kimura Y; Kawada J; Hirao M; Hirota M; Fujitani K; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Satoh T
    Int J Clin Oncol; 2020 Dec; 25(12):2035-2043. PubMed ID: 32926227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase-I study of second-line S-IROX for unresectable pancreatic cancer after gemcitabine plus nab-paclitaxel failure.
    Okuno M; Mukai T; Iwata K; Takagi A; Ito Y; Ohashi Y; Tezuka R; Iwasa Y; Iwata S; Tomita E
    Med Oncol; 2024 Jul; 41(8):195. PubMed ID: 38967720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial.
    Tehfe M; Dowden S; Kennecke H; El-Maraghi R; Lesperance B; Couture F; Letourneau R; Liu H; Romano A
    Adv Ther; 2016 May; 33(5):747-59. PubMed ID: 27085323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
    Huang DZ; Xiong JP; Xu N; Yan Z; Zhuang ZX; Yu Z; Wan HP; Zhang Y; Deng T; Zheng RS; Guo ZQ; Hu CH; Wang ML; Yu ZH; Yao Y; Meng JC; Ba Y
    Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):865-8. PubMed ID: 23291139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial).
    Sai S; Toyoda M; Tobimatsu K; Satake H; Yasui H; Kimbara S; Koyama T; Fujishima Y; Imamura Y; Funakoshi Y; Kiyota N; Toyama H; Kodama Y; Minami H
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):65-71. PubMed ID: 33098471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer.
    Yamaue H; Satoi S; Kanbe T; Miyazawa M; Tani M; Kawai M; Hirono S; Okada K; Yanagimoto H; Kwon AH; Mukouyama T; Tsunoda H; Chijiiwa K; Ohuchida J; Kato J; Ueda K; Yamaguchi T; Egawa S; Hayashi K; Shirasaka T
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):97-102. PubMed ID: 24146260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.